Literature DB >> 2783923

Recruitment and activation of tumor-specific immune T cells in situ: functional studies using a sponge matrix model.

U Zangemeister1, K Thiede, V Schirrmacher.   

Abstract

The activation of tumor-specific precursor cytotoxic T lymphocytes (CTLP) into cytotoxic T cells (CTL) was demonstrated in situ using the well-defined, highly metastatic ESb tumor as murine model system. Ten days after optimal immunization of syngeneic mice with a sublethal dose of live ESb tumor cells in the pinna, tumor-sensitized non-cytotoxic CTLP were recovered from the spleen and lymph nodes. These cells mature into tumor-specific CTL upon restimulation in vitro. Using a confined sponge matrix compartment, in combination with a specific tumor vaccine (autologous inactivated tumor cells), we induced a CD8+ (Lyt 2+) T-cell-mediated, highly cytotoxic anti-tumor immune response in situ in immunized mice. It was not possible to activate a similar response directly in lymphoid organs such as the spleen. The cytotoxic CD8+ T cells, recovered by simple mechanical pressing of the sponge, were active against the specific tumor cells in a 51Cr-release assay in vitro and also in a Winn neutralization assay in vivo. CTL activity was increased and remained in the non-adherent fraction when the cell mixture, squeezed out of the sponges, was passed over nylon wool. In a cell recruitment assay, the delayed-type hypersensitivity (DTH) potential of the activated sponge-infiltrating T cells was demonstrated by their capacity to recruit circulating host lymphocytes to sites of tumor-cell location in situ.

Entities:  

Mesh:

Year:  1989        PMID: 2783923     DOI: 10.1002/ijc.2910430225

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Functional T lymphocytes infiltrate implanted polyvinyl alcohol foams during surgical wound closure therapy.

Authors:  C Gouttefangeas; M Eberle; P Ruck; M Stark; J E Müller; H D Becker; H G Rammensee; J Pinocy
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice.

Authors:  V Schirrmacher; P von Hoegen; A Griesbach; H J Schild; U Zangemeister-Wittke
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Analysis of effector T cells against the murine syngeneic tumor MethA in mice orally administered antitumor polysaccharide SPR-901.

Authors:  Y Takeda; M Tanaka; H Miyazaki; S Takeo; K Nomoto; Y Yoshikai
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.